Innospec Inc. (NASDAQ:IOSP) has been given a consensus recommendation of “Hold” by the six research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $86.00.

Several brokerages have recently issued reports on IOSP. BidaskClub upgraded shares of Innospec from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 11th. KeyCorp upped their target price on shares of Innospec from $80.00 to $86.00 and gave the company an “overweight” rating in a report on Friday, July 13th. Finally, Zacks Investment Research cut shares of Innospec from a “hold” rating to a “sell” rating in a report on Wednesday.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its holdings in shares of Innospec by 2.5% in the 2nd quarter. BlackRock Inc. now owns 3,820,121 shares of the specialty chemicals company’s stock valued at $292,430,000 after buying an additional 94,111 shares in the last quarter. FMR LLC boosted its holdings in shares of Innospec by 12.6% in the 2nd quarter. FMR LLC now owns 3,570,805 shares of the specialty chemicals company’s stock valued at $273,345,000 after buying an additional 399,488 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Innospec by 0.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,497,213 shares of the specialty chemicals company’s stock valued at $114,612,000 after buying an additional 7,141 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Innospec by 4.5% in the 1st quarter. Wells Fargo & Company MN now owns 1,134,315 shares of the specialty chemicals company’s stock valued at $77,815,000 after buying an additional 48,893 shares in the last quarter. Finally, Champlain Investment Partners LLC boosted its holdings in shares of Innospec by 5.3% in the 1st quarter. Champlain Investment Partners LLC now owns 828,145 shares of the specialty chemicals company’s stock valued at $56,811,000 after buying an additional 41,750 shares in the last quarter. Institutional investors and hedge funds own 93.18% of the company’s stock.

NASDAQ IOSP opened at $76.00 on Monday. The company has a quick ratio of 1.34, a current ratio of 2.28 and a debt-to-equity ratio of 0.26. Innospec has a 52 week low of $55.75 and a 52 week high of $83.20. The company has a market cap of $1.86 billion, a price-to-earnings ratio of 16.31 and a beta of 1.00.

Innospec (NASDAQ:IOSP) last posted its quarterly earnings results on Tuesday, August 7th. The specialty chemicals company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.05). Innospec had a return on equity of 13.83% and a net margin of 4.45%. The firm had revenue of $358.10 million for the quarter. research analysts expect that Innospec will post 4.35 EPS for the current fiscal year.

About Innospec

Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals for use as fuel additives, ingredients for personal care, home care, agrochemical, mining and other applications, and oilfield chemicals worldwide. It operates through four segments: Fuel Specialties, Performance Chemicals, Oilfield Services, and Octane Additives.

See Also: Marijuana Stocks Future Looks Bright

Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.